Skip to main content
. 2022 Jun 14;39(8):3472–3487. doi: 10.1007/s12325-022-02169-3

Fig. 3.

Fig. 3

Treatment algorithm: prescribing SGLT2is for HFrEF in clinical practice by cardiologists: patient assessment, treatment initiation, monitoring, and patient counseling [23, 24, 37, 5355]. Modified from Vardeny O, Vaduganathan M. Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists. JACC Heart Fail 2019;7:169–172, ©2019, with permission from Elsevier Inc. DKA diabetic ketoacidosis, eGFR estimated glomerular filtration rate, HCP healthcare provider, HFrEF heart failure with reduced ejection fraction, LVEF left ventricular ejection fraction, NYHA New York Heart Association, QD once daily, SGLT2i sodium–glucose cotransporter 2 inhibitor, T2D type 2 diabetes